Table 5.

Logistic regression analysis of the association between mir-20a-5p expression levels in stroma, in relation to clinicopathological parameters and breast cancer risk factors.

	N	Odds ratio	95% Confidence interval	p-value
Tumor size	309	0.90	0.67–1.20	0.48
Tumor grade
1	97	Ref	Ref	Ref
2	129	1.22	0.56–2.66	0.61
3	82	1.59	0.70–3.61	0.27
Molecular subgroup
Luminal A	191	Ref	Ref	Ref
Luminal B	63	1.20	0.54–2.64	0.66
HER2-enriched	15	0.98	0.21–4.58	0.98
Basal like	39	1.64	0.68–3.95	0.27
Estrogen receptor
Negative	59	Ref	Ref	Ref
Positive	250	0.82	0.38–1.77	0.62
Progesterone receptor
Negative	97	Ref	Ref	Ref
Positive	202	0.92	0.47–1.80	0.80
HER2
Negative	270	Ref	Ref	Ref
Positive	38	1.08	0.42–2.74	0.88
Ki67
Low	173	Ref	Ref	Ref
High	87	2.02	1.02–4.01	0.043
Lymph node metastasis
No	215	Ref	Ref	Ref
Yes	92	1.30	0.67–2.52	0.44
Distant metastasisa
No	273	Ref	Ref	Ref
Yes	33	1.04	0.38–2.85	0.94
Relapse
No	282	Ref	Ref	Ref
Yes	25	3.02	1.22–7.49	0.017
Menopausal statusb
Post	217	Ref	Ref	Ref
Pre	92	2.81	1.48–5.33	0.002
BMI
Low	274	Ref	Ref	Ref
High	28	0.41	0.09–1.81	0.24
Parity
Nulliparous	31	Ref	Ref	Ref
Parous	278	1.20	0.40–3.61	0.74
Oral contraceptives
Never	114	Ref	Ref	Ref
Ever	184	0.74	0.39–1.40	0.36
Alcohol consumption	302	0.99	0.92–1.07	0.76
Smoking
Never	106	Ref	Ref	Ref
Ever	202	1.24	0.63–2.44	0.54

HER2 Human epidermal growth factor receptor 2. ^aAt any time, ^bAt diagnosis.